Tiziana Life Sciences is trading at $0.91 (down 10.3%) amid a sharp single-stock pullback that contrasts with gains in the broader biotech sector.
- Today’s move appears driven by stock-specific volatility rather than new fundamental news, as there are no fresh company-specific announcements.
- The market had already absorbed the most recent key event, which was the January 16, 2026, $8–8.8 million registered direct offering priced at $1.25 per share.